Literature DB >> 1615584

Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?

J S Teppema1, E C de Boer, P A Steerenberg, A P van der Meijden.   

Abstract

Intravesical administration of Bacillus Calmette-Guérin (BCG) has been shown to be effective in the treatment of patients with superficial bladder cancer. For a better understanding of the mechanism of this antitumor activity, scanning and transmission electron microscope (SEM, TEM) studies were carried out to investigate morphological aspects of the interaction of BCG with the bladder wall in vivo and in vitro. Adherence of BCG to the bladder wall in vivo was studied 1 and 24 h after single or multiple (6x) BCG instillations in intact and in electrocauterized guinea pig bladders. Despite extensive search with SEM for its presence, virtually no BCG was found on the intact urothelium, and BCG was only occasionally observed in the coagulation lesions. SEM and TEM studies revealed adherence and phagocytosis of BCG by the T24 human bladder carcinoma cell line in vitro. Time sequence studies on the phagocytosis and fate of BCG showed that T24 cells are capable of progressively degrading the mycobacteria in phagolysosomes. However, BCG did not alter MHC class II antigen expression on T24 cells in vitro. In contrast, 54 urine sediments and bladder washings of 11 bladder cancer patients, taken prior to or after several intravesical BCG instillations, failed to demonstrate urothelial (tumor) cells showing evidence of BCG phagocytosis (682 cells screened by TEM), while BCG was phagocytized avidly by leukocytes. These data suggest that a direct interaction of BCG with urothelial bladder cells in vivo can be called in question.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615584     DOI: 10.1007/bf00299721

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  30 in total

1.  Local bacillus Calmette-Guerin therapy for superficial bladder cancer: clinical, histological and ultrastructural patterns.

Authors:  P Rigatti; R Colombo; F Montorsi; A Centemero; G Guazzoni; V Di Girolamo; L Galli; E Trabucchi
Journal:  Scand J Urol Nephrol       Date:  1990

2.  Local immune responses after intravesical BCG treatment for carcinoma in situ.

Authors:  M I el-Demiry; G Smith; A W Ritchie; K James; J A Cumming; T B Hargreave; G D Chisholm
Journal:  Br J Urol       Date:  1987-12

3.  Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.

Authors:  J Bubeník; M Baresová; V Viklický; J Jakoubková; H Sainerová; J Donner
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

Review 4.  Bacillus Calmette-Guérin as an anti-tumor agent. The interaction with cells of the mammalian immune system.

Authors:  M Davies
Journal:  Biochim Biophys Acta       Date:  1982-04-29

5.  Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.

Authors:  E C de Boer; W H de Jong; A P van der Meijden; P A Steerenberg; F Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1991

6.  Ultrastructural characterization of normal and damaged membranes of Mycobacterium leprae and of cultivable mycobacteria.

Authors:  M T Silva; P M Macedo
Journal:  J Gen Microbiol       Date:  1984-02

7.  In vivo killing and degradation of Mycobacterium aurum within mouse peritoneal macrophages.

Authors:  M T Silva; R Appelberg; M N Silva; P M Macedo
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

8.  Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.

Authors:  A Böhle; J Gerdes; A J Ulmer; A G Hofstetter; H D Flad
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

9.  The mechanism of human bladder tumor implantation in an in vitro model.

Authors:  D Pode; Y Alon; A T Horowitz; I Vlodavsky; S Biran
Journal:  J Urol       Date:  1986-08       Impact factor: 7.450

10.  HLA-DR expression by high grade superficial bladder cancer treated with BCG.

Authors:  S Prescott; K James; A Busuttil; T B Hargreave; G D Chisholm; J F Smyth
Journal:  Br J Urol       Date:  1989-03
View more
  10 in total

Review 1.  Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.

Authors:  Neelam Mukherjee; Esther Julián; Jordi B Torrelles; Robert S Svatek
Journal:  Vaccine       Date:  2021-10-07       Impact factor: 4.169

2.  Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG.

Authors:  E Pieras-Ayala; J Palou-Redorta; J I Tomero-Ruiz; M Montlleó-González; J Salvador-Bayarri; J Vicente-Rodríguez
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

3.  Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.

Authors:  L T Balemans; P D Vegt; P A Steerenberg; E C De Boer; A Van Swaaij; R E De Vries; A P Van der Meijden; W Den Otter
Journal:  Urol Res       Date:  1994

4.  Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).

Authors:  T M de Reijke; P C Vos; E C de Boer; R F Bevers; W H de Muinck Keizer; K H Kurth; D H Schamhart
Journal:  Urol Res       Date:  1993

5.  Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.

Authors:  M J Stassar; P D Vegt; P A Steerenberg; A P van der Meijden; H D Meiring; M Dessens-Kroon; H G Geertzen; W den Otter
Journal:  Urol Res       Date:  1994

6.  Interaction between bacteria and the lumenal bladder surface: modulation by pentosan polysulfate, an experimental and theoretical approach with clinical implication.

Authors:  D H Schamhart; E C de Boer; K H Kurth
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

7.  Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro.

Authors:  B Schneider; A Thanhäuser; D Jocham; H Loppnow; E Vollmer; J Galle; H D Flad; A J Ulmer; A Böhle
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 8.  New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond.

Authors:  Alessandro Audisio; Consuelo Buttigliero; Marco Donatello Delcuratolo; Elena Parlagreco; Marco Audisio; Antonio Ungaro; Rosario Francesco Di Stefano; Lavinia Di Prima; Fabio Turco; Marcello Tucci
Journal:  Cells       Date:  2022-01-21       Impact factor: 6.600

Review 9.  Role of urothelial cells in BCG immunotherapy for superficial bladder cancer.

Authors:  R F M Bevers; K-H Kurth; D H J Schamhart
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

10.  Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer.

Authors:  Dafina Ilijazi; Walter Pulverer; Iris E Ertl; Ursula Lemberger; Shoji Kimura; Mohammad Abufaraj; David D'Andrea; Benjamin Pradere; Andreas Bruchbacher; Anna Graf; Francesco Soria; Martin Susani; Andrea Haitel; Luca Molinaro; Armin Pycha; Evi Comploj; Stephan Pabinger; Andreas Weinhäusel; Gerda Egger; Shahrokh F Shariat; Melanie R Hassler
Journal:  Cells       Date:  2020-08-05       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.